Novocure Ltd (NVCR)

[dstock07734]

Here is the dissertation by Joseph Anotnios who was the only Ph.D. student under the direct guidance of Dr. Linda Liau.

https://escholarship.org/content/qt0t37x26s/qt0t37x26s.pdf

Take a look at the results from mouse model. The green line corresponds to the currently undergoing combo trial at UCLA.
https://classic.clinicaltrials.gov/ct2/show/NCT04201873?cond=atl-dc&draw=2&rank=1



People always say that medicine success on animal models would not translate to the one on humans. Here is the amazing part. In the case of DCVax-L, the success on animal models translates.

DCVax-L alone was successful on animal models. Then success was achieved in p1 and p3 trial.
DCVax-L + Poly-ICLC was successful on mouse models. in the human trial, five out of nine patients live over 10 years after three doses of the vaccine within 28 days. No SOC was involved.
https://classic.clinicaltrials.gov/ct2/show/NCT01204684?cond=glioblastoma&spons=Jonsson&draw=2&rank=15

DCVax-L + Poly-ICLC + Keytruda was successful on mouse models too. Likewise we see the incredible data on rGBM patients.
https://classic.clinicaltrials.gov/ct2/show/NCT04201873?cond=atl-dc&draw=2&rank=1
This trial needs elaboration. As a matter of fact, the preliminary results from this trial were so successful that after March 2021 which was the last time the PI, Timothy Cloughesy reported to Merck, all the puzzles started moving. Kevin Duffy joined Regeneron. Oncovir who owns the patent of poly-iclc hired several high-caliber professionals. It should be noted that National Cancer Institute is also the sponsor of the trial. No doubt Timothy would report to NCI too. People who really have interest may check who was later promoted to be the director of NCI and later the director of NIH.